Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
FDA Considers New Dupilumab Data for CSU Indication
The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for dupilumab for the treatment of chronic spontaneous urticaria (CSU) in adults and youth aged ≥ 12 years for whom antihistamines are inadequate,…
English